14.29
-0.69%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Tasly Pharmaceutical Group Co
Its shares trade on Shanghai under the ticker 600535.SS. It has been listed since 23 August 2002. In the fiscal year to 31 December 2025, it reported revenue of CN¥8.24bn and net income of CN¥1.11bn. At that date it held total assets of CN¥15.34bn and shareholders' equity of CN¥12.40bn.
Tasly Pharmaceutical Group Co., Ltd. engages in the development, manufacture and distribution of pharmaceutical products. The company is headquartered in Tianjin, Tianjin. The company went IPO on 2002-08-23. The firm's main businesses include the manufacture and sales of traditional Chinese medicines, chemical preparations, chemical raw materials and biological medicines. The firm's main products include Compound Danshen Dropping Pills, Yangxuenao Granules, Yangxuenao Pills, Qishen Yiqi Dropping Pills, Diqing and Shuilinjia. Its products are used to treat cardiovascular and cerebrovascular diseases, tumors, colds, fevers and liver diseases. The firm mainly distributes its products in the domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 23 Aug 2002
- Employees
- 9,183
- Website
- taslypharma.com ↗
Leadership
Pay as last reported
- Mr. Kaijing YanChairman of the Board, since 2015CN¥2.8m
- Mr. Xiaomeng JiangVice Chairman of the Board
- Mr. He SunVice Chairman of the Board, since 2018CN¥2.6m
- Ms. Jie WeiChief Financial OfficerCN¥1.4m
- Mr. Jinyong CaiGeneral Manager, Director, since 2024CN¥1.5m
- Mr. Jie YuDeputy General Manager, Secretary of the BoardCN¥2.5m
- Mr. Shuiping ZhouDeputy General Manager, Director, since 2024CN¥1.4m
- Mr. Kexin LiDirectorCN¥1.8m
- Mr. Xiutao HanIndependent DirectorCN¥116,200
- Ms. Aijian WangIndependent Director, since 2021CN¥200,000
- Mr. Bin ZhangIndependent DirectorCN¥200,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 66
- Environment
- 99
- Social
- 72
- Governance
- 29
- Direct emissions (scope 1)
- 37,369.84 t
- Energy emissions (scope 2)
- 106,327.17 t
- Women in the workforce
- 53.2%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Tasly Pharmaceutical Group employs 9,183 full-time employees in Tianjin, China.
- Tasly's main products include Compound Danshen Dropping Pills and Yangxuenao Granules for cardiovascular treatment.
- Tasly focuses on domestic market distribution for its pharmaceutical products in China.
Weaknesses
- Tasly's main products target cardiovascular and cerebrovascular diseases, limiting market diversity.
- Tasly's distribution is primarily domestic, reducing international market reach.
- Tasly's product range includes traditional Chinese medicines, which may face regulatory challenges.
Opportunities
- Tasly can expand its product line to include more treatments for tumors and liver diseases.
- Tasly may leverage its domestic market presence to enter international markets.
- Tasly can develop new formulations for existing products like Qishen Yiqi Dropping Pills.
Threats
- Tasly faces competition from domestic pharmaceutical companies in China's Health Care sector.
- Tasly's reliance on traditional Chinese medicines may lead to market saturation.
- Tasly's products for colds and fevers could be affected by seasonal demand fluctuations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.